Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.